APR 09, 2018 05:47 PM PDT

Molecularly Attacking Transthyretin Amyloidosis (ATTR)

WRITTEN BY: Nouran Amin

Transthyretin amyloidosis (ATTR) is a slowly progressive disease characterized by the buildup of abnormal deposits of a protein known as amyloid present in the body's organs and tissues. Amyloid deposits most frequently occur in the peripheral nervous system, which affect the nerves that connect the brain and spinal cord to muscles and sensory cells that detect sensations such as touch, pain, heat, and sound.

There are three distinct forms of the ATTR family which are progressive and deadly. These forms are wild-type ATTR cardiomyopathy, mutant ATTR cardiomyopathy, and ATTR polyneuropathy. All these forms are progressive and deadly, and currently no disease-modifying therapies exist that have been approved by the FDA. The progression of all types of ATTR lead to morbidity which causes loss of productivity and quality of life.

 

Now, a clinical stage biopharmaceutical company known as Eidos Therapeutics, Inc is developing novel oral therapy to treat ATTR, this oral therapy is a drug called AG10. “Our clinical data demonstrate that AG10 has a safe, well-tolerated profile and is able to stabilize 100% of plasma TTR at peak concentrations and provide average levels of stabilization greater than 95% at steady-state,” says Neil Kumar, the CEO of Eidos. “Given that increasing levels of stabilization have yielded progressively better clinical results in past trials, our near-complete levels of stabilization suggest that AG10 could be a best-in-class solution. We are targeting ATTR at its source by stabilizing TTR, an approach that is validated by genetics and clinical data.”AG10 works to target ATTR at its roots by binding and stabilizing the TTR tetramers since it is the destabilization that progresses the development of ATTR. In particular, the Eidos’ approach copies a naturally-occurring genetic mutation known as T119M that prevents high-risk individuals from developing ATTR. This form of protection works by stabilizing the TTR tetramer.

When AG10 binds to tetrameric TTR, it creates molecular bonds at the same regions as T119M, which “super-stabilizes” TTR and enhancing survival. The binding highlights the ability of AG10’s, at the highest blood concentrations, to stabilize tetrameric TTR and stop its dissociation into disease-leading TTR monomers. Previous clinical trials in ATTR demonstrate that inhibiting the generation of TTR monomers from circulating in the bloodstream significantly improves clinical outcomes. Eidos believes that AG10 may the best therapeutic treatment. “ATTR diseases are a large and growing unmet need, and together, they represent one of the largest genetically-defined diseases with inadequate standard of care,” says Rajeev Shah, the managing director and portfolio manager at RA Capital which finances Eidos. “We look forward to working with Eidos’ proven management team to bring a disease-modifying treatment for ATTR to market as quickly as possible.”

Sources: Genetics Home Reference, Drug Discovery News

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 06, 2018
Drug Discovery
OCT 06, 2018
New Class of Drugs for Breast Cancer Therapy
Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively be...
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Potential Targeted Treatment for Crohn Disease
Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract. Now,...
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Combination of Drugs Extends Lifespan of C. elegans
In a study published in the journal Developmental Cell, a cocktail of pharmaceutical drugs were recently found to extend the life of the microscopic worm,...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Anti-inflammatory Drug Works Like an Inhibitor
At Karolinska Institutet in Sweden, a team of scientists from multiple disciplines have worked together to develop an inflammation inhibitor. The new anti-...
JAN 15, 2019
Immunology
JAN 15, 2019
A Possible Key to Severe Flu
By studying the impact that NPY and its receptor Y1R have on influenza in mice, the research group has now discovered that NPY produced in lung phagocytes can aggravate influenza....
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Drug Blocks Toxic-Protein Production in ALS
Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in ...
Loading Comments...